ASX Share rice
Tue 11 Aug 2020 - 10:46:am (Sydney)

CSL Share Price

CSL LIMITEDCSLPharmaceuticals, Biotechnology & Life Sciences

CSL Company Information

Name:

CSL Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

45 Poplar Road Parkville VIC Australia 3052

Phone:

61 3 9389 1911

Full Time Employees:

25031

MD, CEO & Exec. Director:

Mr. Paul R. Perreault

Chief Financial Officer:

Mr. David Mark Lamont ACA, BCom

Exec. VP of Legal & Group Gen. Counsel:

Mr. Gregory Boss BS(Hons), J.D.

Exec. VP & Chief HR Officer:

Ms. Elizabeth Walker

Exec. VP & Chief Commercial Officer:

Mr. William Campbell

Company Overview:

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CSL Share Price Information

Shares Issued:

453.88M

Market Capitalisation:

$125.42B

Dividend per Share:

$2.93

Ex Dividend Date:

2020-03-11

Dividend Yield:

1.06%

Revenue (TTM):

$8.94B

Revenue Per Share (TTM):

$19.73

Earnings per Share:

$4.417

Profit Margin:

0.2243

Operating Margin (TTM):

$0.29

Return On Assets (TTM):

$0.13

Return On Equity (TTM):

$0.37

Quarterly Revenue Growth (YOY):

0.09

Gross Profit(TTM):

$4.78B

Diluted Earnings Per Share (TTM):

$4.417

QuarterlyEarnings Growth(YOY):

0.072

CSL CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-1,835,591,045.20

Change To Liabilities:

$13M

Total Cashflow From Investing Activities:

$-1,287,300,000

Net Borrowings:

$288.30M

Net Income:

$2.74B

Total Cash From Operating Activities:

$1.64B

Depreciation:

$310.30M

Dividends Paid:

$-1,150,434,906.60

Change To Inventory:

$-367,000,000

Change To Account Receivables:

$-367,100,000

Capital Expenditures:

$1.83B

CSL Income Statement

Income Date:

2019-06-30

Income Before Tax:

$3.34B

Net Income:

$2.74B

Gross Profit:

$6.77B

Operating Income:

$3.53B

Other Operating Expenses:

$5.66B

Interest Expense:

$251.96M

Income Tax Expense:

$422.40M

Total Revenue:

$12.13B

Total Operating Expenses:

$3.24B

Cost Of Revenue:

$5.36B

CSL Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$1.11B

Total Liabilities:

$10.07B

Total Stockholder Equity:

$7.49B

Other Current Liabilities:

$3.99M

Total Assets:

$17.56B

Retained Earnings:

$13.71B

Other Liabilities:

$632.70M

Good Will:

$1.57B

Other Assets:

$401.80M

Cash:

$0.94B

Total Current Liabilities:

$3.12B

Short-Term Debt:

$595.32M

Property - Plant & Equipment:

$4.48B

Net Tangible Assets:

$3.37B

Long-Term Investments:

$14.12M

Total Current Assets:

$7.90B

Long-Term Debt:

$6.02B

Net Receivables:

$1.82B

Short-Term Investments:

$9.66B

Inventory:

$4.33B

Accounts Payable:

$602.60M

Non Currrent Assets (Other):

$9.66B

Short-Term Investments:

$9.66

Non Current Liabilities (Other):

$49.34M

Non Current Liabilities Total:

$6.95B

CSL Share Price History

CSL News

30 Jul, 2020
Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season
22 Jul, 2020
Australian shares closed lower on Wednesday, dragged down by the healthcare sector, as a record surge in COVID-19 cases in the country dented investor sentiment. Australia recorded 501 new coronavirus infections in the past 24 hours, its highest since the epidemic took hold in March, with Victoria state, of which Melbourne is the capital, accounting for almost 97% of the new cases. "The fact that metro Melbourne, which is about 5 million people, has already been in a lockdown for the last couple of weeks and still not seeing a drop in cases is probably something to be a little concerned about," said Steven Daghlian, market analyst at CommSec.
09 Jul, 2020
Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Award for coagulation research just ahead of the first ever virtual congress of the International Society on Thrombosis and Hemostasis (ISTH).
07 Jul, 2020
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
06 Jul, 2020
Global biotherapeutics leader CSL Behring today announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19 related pneumonia.
24 Jun, 2020
Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure (NASDAQ: QURE), a leading gene therapy company. The AMT-061 program, currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with hemophilia B.
LEXINGTON, Mass. and AMSTERDAM, June 24, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B. Etranacogene dezaparvovec consists of an AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua). Under the terms of the agreement, uniQure will receive a $450 million upfront cash payment and be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones.
19 Jun, 2020
The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June 19th: Yi Deng, Ph.D., Dean and Isaac L. Auerbach Professor in the College of Computing and Informatics at Drexel University, and Bill Mezzanotte, M.D., M.P.H., Executive Vice President, Head of Research and Development and Chief Medical Officer at CSL Behring.
12 Jun, 2020
Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever Virtual Summit June 14-19, 2020. WFH is an international not-for-profit organization that works to improve the lives of people with hemophilia and other inherited bleeding disorders, and CSL Behring is proud to be a long-term partner with the WFH to connect the global bleeding disorders community.
08 Jun, 2020
Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients. The companies entered into a strategic partnership in 2017 to expedite the development of clazakizumab with the option for CSL Behring to acquire Vitaeris, along with this important product candidate. With this acquisition, clazakizumab joins CSL842 and CSL964 as part of CSL Behring's portfolio of products in late-stage development to address significant unmet needs in the transplant community.
CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an investigational novel Factor XIIa-inhibitory monoclonal antibody (FXIIa mAb) in development as a preventive treatment in hereditary angioedema (HAE). The data, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress 2020, showed that the study met its primary endpoint, demonstrating reduced number of attacks compared to placebo in patients with HAE. Mean percentage reductions were 88.68%, 98.94%, and 90.50% in three garadacimab groups - 75, 200, and 600 mg subcutaneous (SC) - versus placebo. The study also showed garadacimab to be well-tolerated. HAE is a rare, genetic and potentially life-threatening condition that causes painful, debilitating and unpredictable episodes of swelling of the abdomen, larynx, face and extremities, among other areas of the body. Garadacimab inhibits the plasma protein, FXIIa. FXIIa initiates the cascade of events that lead to edema formation. By targeting FXIIa, garadacimab can prevent the initiation of this cascade.
05 Jun, 2020
CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into a new, significant partnering agreement to accelerate the development, manufacture and distribution of a COVID-19 vaccine candidate which has been pioneered by researchers at UQ. The agreement formalises the support provided by CSL to UQ and CEPI from the outset of the pandemic earlier this year.
02 Jun, 2020
Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.
01 Jun, 2020
Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.
27 May, 2020
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives.
26 May, 2020
U.S. pharmacy chains are preparing a big push for flu vaccinations when the season kicks off in October, hoping to curb tens of thousands of serious cases that could coincide with a second wave of coronavirus infections. CVS Health Corp, one of the largest U.S. pharmacies, said it is working to ensure it has vaccine doses available for an anticipated surge in customers seeking shots to protect against seasonal influenza. Rival chain Rite Aid Corp has ordered 40 percent more vaccine doses to meet the expected demand.
A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor groups has come together to support the rapid development of potential new therapies for patients with COVID-19. Working together under the "The Fight Is In Us" campaign, the coalition is seeking to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their blood plasma, which contains vital antibodies that have fought off the disease and could now help others do the same.
18 May, 2020
In 2013, Paul Perreault was appointed CEO of CSL Limited (ASX:CSL). This report will, first, examine the CEO...
07 May, 2020
The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19, is rapidly building momentum. Its membership has expanded globally to include 10 plasma companies, and now also includes global organizations from outside the plasma industry who are providing vital support to encourage more people to donate plasma.
06 May, 2020
Australian biotech firm CSL Ltd said on Wednesday it will start local development of an immunoglobulin product to treat serious cases of COVID-19, the disease caused by the novel coronavirus. The company's unit CSL Behring will develop the immunoglobulin product at its Melbourne-based Broadmeadows facility using antibodies from plasma collected from people who have recovered from COVID-19, CSL said in a statement on its website. CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said.

CSL Dividend Payments

EX-Date Dividend Amount
2010-03-08$0.3500
2010-09-13$0.4500
2011-03-07$0.3500
2011-09-19$0.4500
2012-03-13$0.3600
2012-09-17$0.4700
2013-03-04$0.4866
2013-09-09$0.5698
2014-03-04$0.5888
2014-09-08$0.6485
2015-03-15$0.7439
2015-09-07$0.8999
2016-03-22$0.8147
2016-09-13$0.8867
2017-03-14$0.8378
2017-09-12$0.9153
2018-03-13$1.0050
2018-09-11$1.2782
2019-03-12$1.2032
2019-09-10$1.4546
2020-03-10$1.4713

CSL Dividends (last 11 Years)